All Industries

Top Oncology Companies

128 Oncology companies, sorted by total funding raised.

Elephas Biosciences

Biosciences company developing precision oncology platforms; headquartered in Madison, Wisconsin.

Madison, United States51–200Biotech, Oncology
Extension Round·$136.5M·Nov 2025
A
AdicetIPO

Adicet Bio is a clinical-stage biotech developing off-the-shelf allogeneic gamma delta T cell the...

Redwood City, United States51–200Biotech, Healthcare
Series B·$131.0M·Oct 2019
AtrecaClosed

Biopharma startup developing cancer treatments based on human immune response.

Redwood City, United States11–50Biotech, Oncology
Series C·$125.0M·Sep 2018
Atomwise

Artificial intelligence for drug discovery.

San Francisco, United States51–200Biotech, Artificial Intelligence
Series B·$123.0M·Aug 2020
MediLink Therapeutics

Innovative ADC drug development company focused on next-generation antibody-drug conjugates for c...

Suzhou, ChinaAntibody Drug Conjugates, Oncology
Series B·$120.0M·Mar 2022
Storm Therapeutics

RNA-targeting cancer drug discovery and development company.

Cambridge, United States11–50Biotech, Healthcare
Series C·$119.4M·May 2026
Nkarta TherapeuticsIPO

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural ...

South San Francisco, United States51–200Biotech, Oncology
Series B·$114.0M·Sep 2019
Atara BiotherapeuticsIPO

Clinical-stage allogeneic T-cell immunotherapy company developing off-the-shelf cell therapies fo...

Thousand Oaks, United States201–500Biotech, Immunotherapy
Series B·$110.5M·Jan 2014
Dispatch Biotherapeutics

Clinical-stage immunotherapy company developing the Flare platform to expand curative potential o...

Biotech, Immunotherapy
Series A·$106.0M·Jul 2025
AffimedIPO

German-domiciled and NASDAQ-traded company developing a variety of immuno-oncology therapeutics.

Heidelberg, Germany51–200Biotech, Oncology
Series E·$101.0M·Sep 2014
Stipple Bio

Biotech developing precision cancer therapies.

Cambridge, United StatesBiotech, Oncology
Series A·$100.0M·Apr 2026
VYRIAD INC

R&D company with 4 SBIR/STTR awards from Department of Health and Human Services.

ROCHESTER, United States11–50Biotech, Oncology
Series B·$95.0M·Dec 2025
Faeth Therapeutics

Data-driven company with deep understanding of how nutrients influence tumor growth

Biotech, Oncology
Series B·$92.0M·Oct 2025
Cleave Biosciences

Discovering and developing novel small molecule therapies for difficult-to-treat cancers

Burlingame, United States11–50Biotech, Oncology
Series B·$89.0M·Aug 2016
PT
Prelude TherapeuticsIPO

Precision oncology company developing innovative medicines targeting areas of high unmet need in ...

Wilmington, United States51–200Biotech, Oncology
Series C·$85.0M·Aug 2020
Recludix Pharma

Recludix is a leader in developing platform approaches to discover potent and selective inhibitor...

San Diego11–50Biotech, Oncology
Series B·$81.5M·Jan 2026
Mitra Biotech

Biotechnology company specializing in personalized cancer treatment and oncology drug development...

United States11–50Biotech, Healthcare
Series C·$79.2M·Jul 2018
Notable LabsIPO

Personalized drug discovery for blood cancer.

Foster City, United States11–50Biotech, Drug Discovery
Venture Round·$77.4M·Feb 2023
AnHeart TherapeuticsAcquired

Clinical-stage biopharmaceutical company developing precision oncology therapeutics, including ta...

New York, China51–200Biotech, Oncology
Series B·$75.6M·Dec 2021
PMV PharmaIPO

Precision oncology company developing first-in-class small molecule therapies that reactivate mut...

Princeton, United States11–50Biotech, Oncology
Series B·$74.0M·Dec 2014
Alpha Biopharma

专注于创新药物从临床研发到商业化运作成功;致力于开发临床急需的创新治疗药物

Shanghai, China11–50Biotech, Oncology
Series B·$73.0M·Apr 2022
Link Cell Therapies

Developing logic-gate CAR T cell therapies for solid tumors, founded by Stanford researchers in p...

Stanford, United States1–10Biotech, Oncology
Series A·$72.0M·Dec 2025
Loxo OncologyClosed

Biopharma company developing targeted cancer therapies for genetically-defined patient populations

United States51–200Biotech, Oncology
Series B·$57.0M·May 2014
VeracyteIPO

Veracyte is a global cancer diagnostics company that provides genomic tests to help clinicians di...

South San Francisco, United States501–1000Biotech, Diagnostics
Series C·$56.3M·Jun 2013
Hope Medicine

Hope Medicine (HopeMed) is a clinical-stage biopharmaceutical company focused on researching, dev...

Shanghai, ChinaBiotech, Oncology
Venture Round·$56.0M·Feb 2024